ELC 5-year Focus, Funding, and Impact

ELC Cooperative Agreement: Focus for the next 5 years, 2019 – 2023

The 2019-23 Notice of Funding Opportunity (NOFO) gives ELC the opportunity to emphasize public health programs while retaining recipients’ ability to work on discrete projects relevant to their populations (e.g., mycotics, Legionella, parasitic disease, rabies, etc.). ELC-funded activities are divided into four compatible, cross-cutting programs:

  • Cross-cutting Epidemiology and Laboratory Capacity Program
  • Foodborne, Waterborne, Enteric, and Environmentally Transmitted Diseases Program
  • Healthcare-associated Infections and Antibiotic Resistance Program
  • Vector-borne Diseases Program

ELC’s Funding Framework

  • Offers opportunities to implement cross-cutting prevention and intervention projects with an increased focus on integration, leadership and flexibility:
    • Data Modernization Project – New in 2020
    • ELC Leadership, Management and Administration Project – Added in 2019
  • Improves coordination of the cooperative agreement while maintaining valued flexibility
  • Maintains opportunities for disease-specific or categorical funding that target specific infectious diseases and other public health threats of importance.
  • Facilitates programmatic growth.
  • Eases administrative burden on both the ELC and its recipients.

Current Funding

2021 Award by Jurisdiction

2021 Award by Jurisdiction pdf icon[PDF – 1 page]

COVID-19 Funding by Jurisdiction

COVID-19 Funding by Jurisdiction pdf icon[PDF – 1 page]

Awards prior to 2021

2020 ELC Award by Jurisdiction

2020 ELC Awards by funding CDC [PDF – 1 page]

Public Health Impact

As Americans are increasingly affected by infections emerging anywhere in the world, finding and stopping infectious disease health threats is essential to protecting public health and saving lives. Communities across the nation benefit from the actions taken by state, local, and territorial public health departments to detect, respond, prevent, and control known and emerging (or re-emerging) infectious diseases. Examples of other benefits:

  • Preventing future outbreaks
  • Responding quickly to occurrences of infectious diseases
  • Executing prevention and control strategies leading to decreased infectious diseases deaths and illnesses
  • Improving health outcomes, health care quality, and health equity